Autolus Therapeutics plc
AUTL
$1.60
$0.021.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.39M | 51.13M | 29.93M | 9.01M | 10.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.39M | 51.13M | 29.93M | 9.01M | 10.12M |
| Cost of Revenue | 181.48M | 160.61M | 144.40M | 119.47M | 105.46M |
| Gross Profit | -106.09M | -109.48M | -114.46M | -110.46M | -95.34M |
| SG&A Expenses | 138.20M | 138.78M | 129.83M | 121.47M | 110.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 345.58M | 325.29M | 300.13M | 276.50M | 251.13M |
| Operating Income | -270.20M | -274.16M | -270.19M | -267.49M | -241.01M |
| Income Before Tax | -285.56M | -220.19M | -223.67M | -234.37M | -219.14M |
| Income Tax Expenses | 1.97M | 4.62M | 4.11M | 3.76M | 1.53M |
| Earnings from Continuing Operations | -287.53 | -224.80 | -227.78 | -238.13 | -220.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -287.53M | -224.80M | -227.78M | -238.13M | -220.66M |
| EBIT | -270.20M | -274.16M | -270.19M | -267.49M | -241.01M |
| EBITDA | -260.38M | -264.90M | -261.53M | -259.31M | -233.30M |
| EPS Basic | -1.08 | -0.84 | -0.86 | -0.89 | -0.87 |
| Normalized Basic EPS | -0.67 | -0.52 | -0.53 | -0.55 | -0.54 |
| EPS Diluted | -1.08 | -0.84 | -0.86 | -0.89 | -0.87 |
| Normalized Diluted EPS | -0.67 | -0.52 | -0.53 | -0.55 | -0.54 |
| Average Basic Shares Outstanding | 1.06B | 1.06B | 1.06B | 1.06B | 1.02B |
| Average Diluted Shares Outstanding | 1.06B | 1.06B | 1.06B | 1.06B | 1.02B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |